Survival of adults with cancers of bone or soft tissue in Europe—Report from the EUROCARE-5 study

C.A. Stiller, L. Botta, D.H. Brewster, V.K.Y. Ho, A.M. Frezza, J. Whelan, P.G. Casali, A. Trama, G. Gatta, the EUROCARE-5 Working Group, Roberta De Angelis

Research output: Contribution to journalArticle

Abstract

Background: Five-year relative survival (RS) of adults with bone and soft-tissue cancers in Europe was still
Original languageEnglish
Pages (from-to)146-153
Number of pages8
JournalCancer Epidemiology
Volume56
DOIs
Publication statusPublished - 2018

Fingerprint

Bone Neoplasms
Bone and Bones
Neoplasms

Keywords

  • Bone cancer
  • Europe
  • Population-based cancer registries
  • Rare cancers
  • Soft-tissue cancer
  • Survival
  • adolescent
  • adult
  • aged
  • Article
  • Austria
  • Belgium
  • bone cancer
  • Bulgaria
  • cancer epidemiology
  • cancer patient
  • cancer registry
  • cancer survival
  • cartilage cancer
  • cohort analysis
  • controlled study
  • Croatia
  • Denmark
  • Estonia
  • female
  • Finland
  • follow up
  • France
  • Germany
  • human
  • Iceland
  • Ireland
  • Latvia
  • Lithuania
  • major clinical study
  • male
  • Malta
  • middle aged
  • Norway
  • Poland
  • Portugal
  • prediction
  • priority journal
  • Slovakia
  • Slovenia
  • soft tissue cancer
  • Spain
  • Sweden
  • Switzerland
  • trend study

Cite this

Survival of adults with cancers of bone or soft tissue in Europe—Report from the EUROCARE-5 study. / Stiller, C.A.; Botta, L.; Brewster, D.H.; Ho, V.K.Y.; Frezza, A.M.; Whelan, J.; Casali, P.G.; Trama, A.; Gatta, G.; Group, the EUROCARE-5 Working; De Angelis, Roberta.

In: Cancer Epidemiology, Vol. 56, 2018, p. 146-153.

Research output: Contribution to journalArticle

Stiller, CA, Botta, L, Brewster, DH, Ho, VKY, Frezza, AM, Whelan, J, Casali, PG, Trama, A, Gatta, G, Group, TEUROCAREW & De Angelis, R 2018, 'Survival of adults with cancers of bone or soft tissue in Europe—Report from the EUROCARE-5 study', Cancer Epidemiology, vol. 56, pp. 146-153. https://doi.org/10.1016/j.canep.2018.08.010
Stiller, C.A. ; Botta, L. ; Brewster, D.H. ; Ho, V.K.Y. ; Frezza, A.M. ; Whelan, J. ; Casali, P.G. ; Trama, A. ; Gatta, G. ; Group, the EUROCARE-5 Working ; De Angelis, Roberta. / Survival of adults with cancers of bone or soft tissue in Europe—Report from the EUROCARE-5 study. In: Cancer Epidemiology. 2018 ; Vol. 56. pp. 146-153.
@article{3c034433bff449cbbd6cbe93c02012f5,
title = "Survival of adults with cancers of bone or soft tissue in Europe—Report from the EUROCARE-5 study",
abstract = "Background: Five-year relative survival (RS) of adults with bone and soft-tissue cancers in Europe was still",
keywords = "Bone cancer, Europe, Population-based cancer registries, Rare cancers, Soft-tissue cancer, Survival, adolescent, adult, aged, Article, Austria, Belgium, bone cancer, Bulgaria, cancer epidemiology, cancer patient, cancer registry, cancer survival, cartilage cancer, cohort analysis, controlled study, Croatia, Denmark, Estonia, female, Finland, follow up, France, Germany, human, Iceland, Ireland, Latvia, Lithuania, major clinical study, male, Malta, middle aged, Norway, Poland, Portugal, prediction, priority journal, Slovakia, Slovenia, soft tissue cancer, Spain, Sweden, Switzerland, trend study",
author = "C.A. Stiller and L. Botta and D.H. Brewster and V.K.Y. Ho and A.M. Frezza and J. Whelan and P.G. Casali and A. Trama and G. Gatta and Group, {the EUROCARE-5 Working} and {De Angelis}, Roberta",
note = "Export Date: 12 April 2019 Correspondence Address: Botta, L.; Evaluative Epidemiology Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto nazionale dei tumori di Milano, Via Venezian 1, Italy; email: laura.botta@istitutotumori.mi.it Funding details: Compagnia di San Paolo Funding details: Fondazione Cariplo Funding text 1: This work was supported by Compagnia di San Paolo, Fondazione Cariplo , European Commission , and Italian Ministry of Health . References: Forman, D., Bray, F., Brewster, D.H., (2014) Cancer Incidence in Five Continents Volume X. IARC Scientific Publication No. 164, , IARC Lyon; Storm, H.H., Survival of adult patients with cancer of soft tissues or bone in Europe. EUROCARE Working Group (1998) Eur. J. Cancer, 34, pp. 2212-2217; Sant, M., Allemani, C., Santaquilani, M., EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary (2009) Eur. J. Cancer, 45, pp. 931-991; Stiller, C.A., Trama, A., Serraino, D., Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project (2013) Eur. J. Cancer, 49, pp. 684-695; Rossi, S., Baili, P., Capocaccia, R., The EUROCARE-5 study on cancer survival in Europe 1999-2007: database, quality checks and statistical analysis methods (2015) Eur. J. Cancer, 51, pp. 2104-2119; De Angelis, R., Francisci, S., Baili, P., The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis (2009) Eur. J. Cancer, 45, pp. 909-930; De Angelis, R., Sant, M., Coleman, M.P., Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE–5-a population-based study (2014) Lancet Oncol., 15, pp. 23-34; Corazziari, I., Quinn, M., Capocaccia, R., Standard cancer patient population for age standardising survival ratios (2004) Eur. J. Cancer, 40, pp. 2307-2316; Ederer, F., Axtell, L.M., Cutler, S.J., The relative survival rate: a statistical methodology (1961) Cancer Inst. Monogr., 6, pp. 101-121; Brenner, H., Gefeller, O., An alternative approach to monitoring cancer patient survival (1996) Cancer, 78, pp. 2004-2010; Parkin, D.M., Hakulinen, T., Analysis of survival (1991) Cancer Registration: Principles and Methods. IARC Scientific Publication No. 95, pp. 159-176. , O.M. Jensen D.M. Parkin R. MacLennan IARC Lyon; Maretty-Nielsen, K., Aggerholm-Pedersen, N., Keller, J., Safwat, A., Baerentzen, S., Pedersen, A.B., Relative mortality in soft tissue sarcoma patients: a Danish population-based cohort study (2014) BMC Cancer, 14, p. 682; Rosenberg, A.E., WHO Classification of Soft Tissue and Bone, fourth edition: summary and commentary (2013) Curr. Opin. Oncol., 25, pp. 571-573; Trama, A., Marcos-Gragera, R., S{\'a}nchez P{\'e}rez, M.J., Data quality in rare cancers registration: the report of the RARECARE data quality study (2017) Tumori, 103, pp. 22-32; Gatta, G., Capocaccia, R., Botta, L., Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet - a population-based study (2017) Lancet Oncol., 18, pp. 1022-1039; Whelan, J., McTiernan, A., Cooper, N., Incidence and survival of malignant bone sarcomas in England 1979-2007 (2012) Int. J. Cancer, 131, pp. E508-517; Ray-Coquard, I., Montesco, M.C., Coindre, J.M., Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions (2012) Ann. Oncol., 23, pp. 2442-2449; Whelan, J.S., Bielack, S.S., Marina, N., EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment (2015) Ann. Oncol., 26, pp. 407-414; Quaglia, A., Tavilla, A., Shack, L., The cancer survival gap between elderly and middle-aged patients in Europe is widening (2009) Eur. J. Cancer, 45, pp. 1006-1016; ESMO/European Sarcoma Network Working Group, Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2014) Ann. Oncol., 25, pp. iii113-123; ESMO/European Sarcoma Network Working Group, Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2014) Ann. Oncol., 25, pp. iii102-112; Le Saux, O., Falandry, C., Gan, H.K., Inclusion of elderly patients in oncology clinical trials (2016) Ann. Oncol., 27, pp. 1799-1804; Issels, R.D., Lindner, L.H., Verweij, J., Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study (2010) Lancet Oncol., 11, pp. 561-570; Judson, I., Verweij, J., Gelderblom, H., Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial (2014) Lancet Oncol., 15, pp. 415-423; van der Graaf, W.T., Blay, J.Y., Chawla, S.P., Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial (2012) Lancet, 379, pp. 1879-1886; Blay, J.Y., Leahy, M.G., Nguyen, B.B., Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas (2014) Eur. J. Cancer, 50, pp. 1137-1147; Whelan, J.S., Jinks, R.C., McTiernan, A., Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials (2012) Ann. Oncol., 23, pp. 1607-1616; Ferrari, S., Ruggieri, P., Cefalo, G., Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1 (2012) J. Clin. Oncol., 30, pp. 2112-2118; Piperno-Neumann, S., Le Deley, M.C., Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial (2016) Lancet Oncol., 17, pp. 1070-1080; van Maldegem, A.M., Bov{\'e}e, J.V., Gelderblom, H., Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013 (2014) Clin. Sarcoma Res., 4, p. 11; Andritsch, E., Beishon, M., Bielack, S., ECCO essential requirements for quality cancer care: soft tissue sarcoma in adults and bone sarcoma. A critical review (2017) Crit. Rev. Oncol. Hematol., 110, pp. 94-105; Blay, J.Y., Soibinet, P., Penel, N., Improved survival using specialized multidisciplinary board in sarcoma patients (2017) Ann. Oncol., 28, pp. 2852-2859; Minicozzi, P., Walsh, P.M., S{\'a}nchez, M.J., Is low survival for cancer in Eastern Europe due principally to late stage at diagnosis? (2018) Eur. J. Cancer, 93, pp. 127-137; Le Deley, M.C., Paulussen, M., Lewis, I., Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial (2014) J. Clin. Oncol., 32, pp. 2440-2448; Lorigan, P., Verweij, J., Papai, Z., Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft tissue and Bone Sarcoma Group Study (2007) J. Clin. Oncol., 25, pp. 3144-3150; Reichardt, P., Nielsen, O.S., Bauer, S., Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II–study of the EORTC Soft tissue and Bone Sarcoma Group (2007) Eur. J. Cancer, 43, pp. 1017-1022; Sch{\"o}ffski, P., Ray-Coquard, I.L., Cioffi, A., Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes (2011) Lancet Oncol., 12, pp. 1045-1052; Woll, P.J., Reichardt, P., Le Cesne, A., Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial (2012) Lancet Oncol., 13, pp. 1045-1054; Gelderblom, H., Blay, J.Y., Seddon, B.M., Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study (2014) Eur. J. Cancer, 50, pp. 388-396; Blay, J.Y., Brahmi, M., Ray-Coquard, I., European Journal of Cancer's biennial report on soft tissue and visceral sarcomas or the rapid evolution of treatment concepts in sarcomas (2017) Eur. J. Cancer, 70, pp. 83-86; Vos, M., Sleiffer, S., EJC's biennial report on metastatic soft tissue sarcoma: state of the art and future perspectives (2018) Eur. J. Cancer, 88, pp. 87-91; Ray-Coquard, I., Pujade Lauraine, E., Le Cesne, A., Improving treatment results with reference centres for rare cancers: where do we stand? (2017) Eur. J. Cancer, 77, pp. 90-98; http://jointactionrarecancers.eu/UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052665504&doi=10.1016{\%}2fj.canep.2018.08.010&partnerID=40&md5=e6278ff2a4578031c2bf5cf333e6b471",
year = "2018",
doi = "10.1016/j.canep.2018.08.010",
language = "English",
volume = "56",
pages = "146--153",
journal = "Cancer Epidemiology",
issn = "1877-7821",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Survival of adults with cancers of bone or soft tissue in Europe—Report from the EUROCARE-5 study

AU - Stiller, C.A.

AU - Botta, L.

AU - Brewster, D.H.

AU - Ho, V.K.Y.

AU - Frezza, A.M.

AU - Whelan, J.

AU - Casali, P.G.

AU - Trama, A.

AU - Gatta, G.

AU - Group, the EUROCARE-5 Working

AU - De Angelis, Roberta

N1 - Export Date: 12 April 2019 Correspondence Address: Botta, L.; Evaluative Epidemiology Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto nazionale dei tumori di Milano, Via Venezian 1, Italy; email: laura.botta@istitutotumori.mi.it Funding details: Compagnia di San Paolo Funding details: Fondazione Cariplo Funding text 1: This work was supported by Compagnia di San Paolo, Fondazione Cariplo , European Commission , and Italian Ministry of Health . References: Forman, D., Bray, F., Brewster, D.H., (2014) Cancer Incidence in Five Continents Volume X. IARC Scientific Publication No. 164, , IARC Lyon; Storm, H.H., Survival of adult patients with cancer of soft tissues or bone in Europe. EUROCARE Working Group (1998) Eur. J. Cancer, 34, pp. 2212-2217; Sant, M., Allemani, C., Santaquilani, M., EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary (2009) Eur. J. Cancer, 45, pp. 931-991; Stiller, C.A., Trama, A., Serraino, D., Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project (2013) Eur. J. Cancer, 49, pp. 684-695; Rossi, S., Baili, P., Capocaccia, R., The EUROCARE-5 study on cancer survival in Europe 1999-2007: database, quality checks and statistical analysis methods (2015) Eur. J. Cancer, 51, pp. 2104-2119; De Angelis, R., Francisci, S., Baili, P., The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis (2009) Eur. J. Cancer, 45, pp. 909-930; De Angelis, R., Sant, M., Coleman, M.P., Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE–5-a population-based study (2014) Lancet Oncol., 15, pp. 23-34; Corazziari, I., Quinn, M., Capocaccia, R., Standard cancer patient population for age standardising survival ratios (2004) Eur. J. Cancer, 40, pp. 2307-2316; Ederer, F., Axtell, L.M., Cutler, S.J., The relative survival rate: a statistical methodology (1961) Cancer Inst. Monogr., 6, pp. 101-121; Brenner, H., Gefeller, O., An alternative approach to monitoring cancer patient survival (1996) Cancer, 78, pp. 2004-2010; Parkin, D.M., Hakulinen, T., Analysis of survival (1991) Cancer Registration: Principles and Methods. IARC Scientific Publication No. 95, pp. 159-176. , O.M. Jensen D.M. Parkin R. MacLennan IARC Lyon; Maretty-Nielsen, K., Aggerholm-Pedersen, N., Keller, J., Safwat, A., Baerentzen, S., Pedersen, A.B., Relative mortality in soft tissue sarcoma patients: a Danish population-based cohort study (2014) BMC Cancer, 14, p. 682; Rosenberg, A.E., WHO Classification of Soft Tissue and Bone, fourth edition: summary and commentary (2013) Curr. Opin. Oncol., 25, pp. 571-573; Trama, A., Marcos-Gragera, R., Sánchez Pérez, M.J., Data quality in rare cancers registration: the report of the RARECARE data quality study (2017) Tumori, 103, pp. 22-32; Gatta, G., Capocaccia, R., Botta, L., Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet - a population-based study (2017) Lancet Oncol., 18, pp. 1022-1039; Whelan, J., McTiernan, A., Cooper, N., Incidence and survival of malignant bone sarcomas in England 1979-2007 (2012) Int. J. Cancer, 131, pp. E508-517; Ray-Coquard, I., Montesco, M.C., Coindre, J.M., Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions (2012) Ann. Oncol., 23, pp. 2442-2449; Whelan, J.S., Bielack, S.S., Marina, N., EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment (2015) Ann. Oncol., 26, pp. 407-414; Quaglia, A., Tavilla, A., Shack, L., The cancer survival gap between elderly and middle-aged patients in Europe is widening (2009) Eur. J. Cancer, 45, pp. 1006-1016; ESMO/European Sarcoma Network Working Group, Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2014) Ann. Oncol., 25, pp. iii113-123; ESMO/European Sarcoma Network Working Group, Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2014) Ann. Oncol., 25, pp. iii102-112; Le Saux, O., Falandry, C., Gan, H.K., Inclusion of elderly patients in oncology clinical trials (2016) Ann. Oncol., 27, pp. 1799-1804; Issels, R.D., Lindner, L.H., Verweij, J., Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study (2010) Lancet Oncol., 11, pp. 561-570; Judson, I., Verweij, J., Gelderblom, H., Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial (2014) Lancet Oncol., 15, pp. 415-423; van der Graaf, W.T., Blay, J.Y., Chawla, S.P., Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial (2012) Lancet, 379, pp. 1879-1886; Blay, J.Y., Leahy, M.G., Nguyen, B.B., Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas (2014) Eur. J. Cancer, 50, pp. 1137-1147; Whelan, J.S., Jinks, R.C., McTiernan, A., Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials (2012) Ann. Oncol., 23, pp. 1607-1616; Ferrari, S., Ruggieri, P., Cefalo, G., Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1 (2012) J. Clin. Oncol., 30, pp. 2112-2118; Piperno-Neumann, S., Le Deley, M.C., Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial (2016) Lancet Oncol., 17, pp. 1070-1080; van Maldegem, A.M., Bovée, J.V., Gelderblom, H., Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013 (2014) Clin. Sarcoma Res., 4, p. 11; Andritsch, E., Beishon, M., Bielack, S., ECCO essential requirements for quality cancer care: soft tissue sarcoma in adults and bone sarcoma. A critical review (2017) Crit. Rev. Oncol. Hematol., 110, pp. 94-105; Blay, J.Y., Soibinet, P., Penel, N., Improved survival using specialized multidisciplinary board in sarcoma patients (2017) Ann. Oncol., 28, pp. 2852-2859; Minicozzi, P., Walsh, P.M., Sánchez, M.J., Is low survival for cancer in Eastern Europe due principally to late stage at diagnosis? (2018) Eur. J. Cancer, 93, pp. 127-137; Le Deley, M.C., Paulussen, M., Lewis, I., Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial (2014) J. Clin. Oncol., 32, pp. 2440-2448; Lorigan, P., Verweij, J., Papai, Z., Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft tissue and Bone Sarcoma Group Study (2007) J. Clin. Oncol., 25, pp. 3144-3150; Reichardt, P., Nielsen, O.S., Bauer, S., Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II–study of the EORTC Soft tissue and Bone Sarcoma Group (2007) Eur. J. Cancer, 43, pp. 1017-1022; Schöffski, P., Ray-Coquard, I.L., Cioffi, A., Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes (2011) Lancet Oncol., 12, pp. 1045-1052; Woll, P.J., Reichardt, P., Le Cesne, A., Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial (2012) Lancet Oncol., 13, pp. 1045-1054; Gelderblom, H., Blay, J.Y., Seddon, B.M., Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study (2014) Eur. J. Cancer, 50, pp. 388-396; Blay, J.Y., Brahmi, M., Ray-Coquard, I., European Journal of Cancer's biennial report on soft tissue and visceral sarcomas or the rapid evolution of treatment concepts in sarcomas (2017) Eur. J. Cancer, 70, pp. 83-86; Vos, M., Sleiffer, S., EJC's biennial report on metastatic soft tissue sarcoma: state of the art and future perspectives (2018) Eur. J. Cancer, 88, pp. 87-91; Ray-Coquard, I., Pujade Lauraine, E., Le Cesne, A., Improving treatment results with reference centres for rare cancers: where do we stand? (2017) Eur. J. Cancer, 77, pp. 90-98; http://jointactionrarecancers.eu/UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052665504&doi=10.1016%2fj.canep.2018.08.010&partnerID=40&md5=e6278ff2a4578031c2bf5cf333e6b471

PY - 2018

Y1 - 2018

N2 - Background: Five-year relative survival (RS) of adults with bone and soft-tissue cancers in Europe was still

AB - Background: Five-year relative survival (RS) of adults with bone and soft-tissue cancers in Europe was still

KW - Bone cancer

KW - Europe

KW - Population-based cancer registries

KW - Rare cancers

KW - Soft-tissue cancer

KW - Survival

KW - adolescent

KW - adult

KW - aged

KW - Article

KW - Austria

KW - Belgium

KW - bone cancer

KW - Bulgaria

KW - cancer epidemiology

KW - cancer patient

KW - cancer registry

KW - cancer survival

KW - cartilage cancer

KW - cohort analysis

KW - controlled study

KW - Croatia

KW - Denmark

KW - Estonia

KW - female

KW - Finland

KW - follow up

KW - France

KW - Germany

KW - human

KW - Iceland

KW - Ireland

KW - Latvia

KW - Lithuania

KW - major clinical study

KW - male

KW - Malta

KW - middle aged

KW - Norway

KW - Poland

KW - Portugal

KW - prediction

KW - priority journal

KW - Slovakia

KW - Slovenia

KW - soft tissue cancer

KW - Spain

KW - Sweden

KW - Switzerland

KW - trend study

U2 - 10.1016/j.canep.2018.08.010

DO - 10.1016/j.canep.2018.08.010

M3 - Article

VL - 56

SP - 146

EP - 153

JO - Cancer Epidemiology

JF - Cancer Epidemiology

SN - 1877-7821

ER -